0

Your Cart is Empty

  • Add description, images, menus and links to your mega menu

  • The Best Psychedelics Stocks | Watch List E-Book


    The Shortcut for Your Investment Research on the Best Psychedelics Stocks.


    I started creating this psychedelics stocks book when I realized curious investors like yourself often ask me for the best stocks I like across a number of different niche sectors on a regular basis.  It’s not always easy to talk to everyone and answer everyone at the same time, but I do enjoy the markets and still want to help people like you in your psychedelics stocks research, so, I created this book and others like it so you can get this information fast and easy. 


    With your purchase, you can download this e-book right away, and it also includes automatic notifications of future updates as well as free downloads of future versions so you'll always stay up to date on the latest public companies getting involved in the psychedelics space.



    Did You Know?


    Scientific channels have been studying the potential application of natural and other psychedelic effect-inducing compounds that could be used in mental health and other therapeutic applications.  In a recent breakthrough, a John Hopkins Medicine study found the application of psilocybin (aka. magic mushrooms) indicated a significant and lasting positive impact, improving the mental health of subjects suffering from depression and anxiety. This has triggered a growing trend towards the research and potential commercialization of psychedelics and similar therapies for health and wellness.


    What’s Included


    • An instantly downloadable e-book list of public companies working in the psychedelics space.

    • Free access to download future versions of the book when new stocks are added and/or the book is updated.



    Features


    • Includes a  complete-as-possible list of public companies working in the psychedelics sector.

    • Covers multiple global exchanges.

    • Easy to download right away upon purchase.

    • Automatic notification of updates to the book via email.

    • An easy free download link is provided for updated versions of the book in the future.

    • Curated by an experienced public company executive and capital markets professional with over 15+ years in the business.



    Benefits


    • A fast and easy way to start your due diligence on this fast-emerging space.

    • The full list is easily downloadable right away after purchase.

    • Save time in your research - I've done the digging so you don’t have to.

    • Move faster than other traders and investors looking at psychedelics stocks.

    • Relax knowing you’ll get updated downloadable versions every time we add new companies to the list.




    How to Use this Psychedelics Stocks Book


    • Download your copy of this book upon purchase.

    • Add the companies in the book to a watchlist on your favorite stock market app / tool.

    • Do your own due diligence on these companies and their projects in this niche before making any investment decision.

    • Follow the companies on social media and subscribe to their email newsletters to stay updated on their progress.



    About the Author


    Chad McMillan


    My professional career has spanned over 15 years of senior executive level management experience in the early-stage capital markets and I have personally led and been involved in numerous multi-million dollar startup financing, merger and acquisition, and reverse takeover transactions with and for what the street endearingly call “penny stock’ public companies.


    From this vantage point, I have personally experienced firsthand the explosive growth that can occur with these companies, and their potential to generate exponential returns for early investors and shareholders in the process.  Now, with many of my friends and colleagues looking to get into and asking me about the markets, I offer some of my own core strategies here to those interested, so you too and participate in this incredible financial growth potential armed with key knowledge, clarity, and confidence.  



    What People Are Saying


    "What is truly groundbreaking is FDA's rightful acknowledgment that.. that the available data suggest that psilocybin may offer a substantial clinical improvement over existing therapies (for depression)."


    Dr. Charles Raison

    The director of clinical and translational research at Usona





    “As patents on many conventional antidepressants begin to expire – and public and regulatory opinion regarding psychedelics is changing – 2021 will be the time that psychedelic therapy casts a spotlight on the limitations of current mental-health care treatments, and highlights a bold alternative.”

    Robin Carhart-Harris

    Wired, UK












    "I have had the pleasure of knowing Chad for nearly five years and have interacted with him in various capacities over that time. Chad has come to be a trusted source on..early-stage finance, and capital markets. His experience as an entrepreneur and company starter has provided him with the on-hands experience that can only be learned in the field."

    James Black
    VP, Listings Development, Canadian Securities Exchange (CSE)












    Why Shop with Me?


    • I offer premium products, without breaking the bank.
    • Fast and easy live chat customer service.
    • Free shipping.
    • Free returns.
    • 30-day money-back guarantee.
    • A proudly independent small business.
    • Secure checkout powered by Shopify



    Your Psychedelics Stocks Research Made Easy.

    Add this psychedelics stocks book to your cart and check out to complete your purchase.  You’ll get a download link right after so you can start studying these stocks in time for the next trading day.



    Legal Disclaimer

    I am not a certified financial analyst, broker, or professionally qualified to offer investment advice. Nothing in this book constitutes or can be construed as investment advice or an offer or solicitation or advice to buy or sell stock or any asset or investment. All of my content should be considered an opinion and my opinions may be based upon information obtained from research of public documents and content available on websites, regulatory filings, various stock exchange websites, and stock information services, through discussions with company representatives, agents, other professionals and investors, my own professional experience, and field visits. My opinions are based upon information believed to be accurate and reliable, but my opinions are not guaranteed or implied to be so. The opinions presented may not be complete or correct; all information is provided without any legal responsibility or obligation to provide future updates. I accept no responsibility and no liability, whatsoever, for any direct, indirect, special, punitive, or consequential damages or loss arising from the use of my content. The information contained in this book is subject to change without notice, may become outdated, and may not be updated. This content reflects my personal opinions, strategies, views and nothing more.